Rising Above Resistance: Transformative Diagnostics in the AMR Fight
The global antimicrobial resistance diagnostics market size is expected to reach USD 6.70 billion by 2030, registering a CAGR of 6.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increased risk of developing drug-resistant bacterial infections, especially in healthcare facilities, and increasing government & non-government bodies’ efforts to combat the threat of AMR are the major factor contributing to market growth. In addition, various strategic initiatives undertaken by leading market players to manage antimicrobial resistance are also contributing to market expansion. For instance, in March 2021, bioMerieux and GIZ collaborated to support the Nigerian center for disease control to strengthen the fight against AMR.
The rising adoption of rapid testing and PoC tests for drug-resistant bacterial infections is anticipated to augment the market over the projected period. Moreover, leading market players such as Danaher, Abbott, and others have a robust product portfolio of rapid diagnostic tests for antimicrobial-resistant infections. Furthermore, the increasing involvement of non-government bodies such as AMR Industry Alliance is assisting regulatory bodies to make strategies to boost the development of diagnostic solutions to manage antimicrobial resistance.
Increasing funding for the development of novel and automated test solutions for the diagnosis of antimicrobial-resistant infections is anticipated to boost market growth over the forecast period. For instance, in May 2022, the European Investment Bank funded more than USD 24 million to POCARED Diagnostics for the R&D of fully automated testing of microbial diseases. POCARED Diagnostics is involved in the development of novel microbiology tests that can provide results within hours.
Antimicrobial resistance is expected to rise in the coming years. Hence, demand for accurate & fast testing options is expected to increase for the effective management and progression monitoring of antimicrobial resistance. According to the CDC, the annual direct healthcare expenditure of antimicrobial resistance is around USD 20 billion in the U.S. High cost of disease management is driving the demand for rapid tests for the diagnosis of infections at an early stage.
Key market players are continuously involved in the development of novel tests to strengthen their market position. Moreover, other strategies such as acquisitions, partnerships, and collaborations are also adopted by leading players to expand their product portfolio in different parts of the globe. For instance, in August 2022, Accelerate Diagnostics and BD announced a collaboration to combat the threat of antimicrobial resistance. As per the deal, BD will provide Accelerate Diagnostics rapid diagnostic solutions for antibiotics-associated resistance to its vast customers.
Antimicrobial Resistance Diagnostics Market Report Highlights
- The PCR segment dominated the market and accounted for the largest revenue share of 24.19% in 2024. Advancements in PCR technology, along with its widespread adoption due to its high accuracy, are key factors driving the significant share of this segment.
- In 2024, the methicillin resistant staphylococcus aureus segment held the largest market share at 28.33%. The rising incidence of MRSA in hospital settings is a key driver for the expansion of this segment.
- In 2024, the hospitals segment led the market, accounting for 48.07% of the revenue share. The growth of this segment is driven by several factors, including the rising incidence of hospital-acquired infections and increased hospitalizations due to antimicrobial-resistant (AMR) infections, which often lead to prolonged hospital stays.
- North America antimicrobial resistance diagnostics market dominated the overall global market with a revenue share of 42.03% in 2024.
Antimicrobial Resistance Diagnostics Market Segmentation
Grand View Research has segmented global antimicrobial resistance diagnostics market report based on technology, pathogen, end-use, and region:
Antimicrobial Resistance Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)
- Microbiology Culture
- Immunoassay
- PCR
- NGS
- Mass Spectrometry
- Rapid & Point of Care
- Others
Antimicrobial Resistance Diagnostics Pathogen Outlook (Revenue, USD Million; 2018 - 2030)
- Drug-resistant Streptococcus pneumoniae (DRSP)
- Drug Resistant Campylobacter (DRC)
- Clostridium difficile (CD)
- Methicillin Resistant Staphylococcus Aureus (MRSA)
- Drug Resistant Neisseria Gonorrhoeae (DRNG)
- Drug Resistant Salmonella (DRNTS)
- Others
Antimicrobial Resistance Diagnostics End Use Outlook (Revenue, USD Million; 2018 - 2030)
- Hospitals
- Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Others
Antimicrobial Resistance Diagnostics Regional Outlook (Revenue, USD Million; 2018 - 2030)
- North America
- US
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Norway
- Denmark
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Mexico
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
List of Key Players
- bioMerieux
- Hoffmann-La Roche Ltd.
- Abbott
- Hologic, Inc.
- BD
- Danaher
- Accelerate Diagnostics, Inc.
- Molsid
- Vela Diagnostics
- Visby Medical, Inc.
- OpGen
Order a free sample PDF of the Antimicrobial Resistance Diagnostics Market Intelligence Study, published by Grand View Research.
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Jeux
- Gardening
- Health
- Domicile
- Literature
- Music
- Networking
- Autre
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness
- IT, Cloud, Software and Technology
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian